CSIMarket
 
Scienture Holdings Inc   (NASDAQ: SCNX)
 

Scienture Holdings Inc's Customers Performance

SCNX



 
SCNX's Source of Revenues During the corresponding time, Scienture Holdings Inc sequentially revenue grew by 510.1 %. While revenue at the Scienture Holdings Inc 's corporate clients

List of SCNX Customers




for the same period Scienture Holdings Inc sequentially revenue grew by 510.1 %.

List of SCNX Customers

Scienture Holdings Inc's Business Units
Losartan Potassium Oral Suspension    116.28 % of total Revenue






Scienture Holdings Inc's Comment on Sales, Marketing and Customers



Scienture LLC operates in the pharmaceutical industry, focusing on markets including hypertension and opioid abuse. The company’s product, Arbli™, is a losartan oral suspension intended for the hypertension market, which comprises treatment options such as ACE inhibitors, ARBs, beta-blockers, diuretics, and calcium channel blockers. The hypertension market includes both branded and generic drugs like Prinvil, Lotensin, Cozaar, Cardizem, Apresoline, Nitrostat, and Toprol-XL. Pending FDA approval, Scienture LLC anticipates that the majority of its product sales will be to pharmaceutical wholesalers, specialty pharmacies, and distributors, who will then supply pharmacies, hospitals, long-term care institutions, and potentially federal and state entities. The company also recognizes opioid abuse as a significant public health issue in the United States, with millions misusing opioids and a high number of drug overdose deaths reported.





Scienture Holdings Inc’s Comment on Sales, Marketing and Customers


Scienture LLC operates in the pharmaceutical industry, focusing on markets including hypertension and opioid abuse. The company’s product, Arbli™, is a losartan oral suspension intended for the hypertension market, which comprises treatment options such as ACE inhibitors, ARBs, beta-blockers, diuretics, and calcium channel blockers. The hypertension market includes both branded and generic drugs like Prinvil, Lotensin, Cozaar, Cardizem, Apresoline, Nitrostat, and Toprol-XL. Pending FDA approval, Scienture LLC anticipates that the majority of its product sales will be to pharmaceutical wholesalers, specialty pharmacies, and distributors, who will then supply pharmacies, hospitals, long-term care institutions, and potentially federal and state entities. The company also recognizes opioid abuse as a significant public health issue in the United States, with millions misusing opioids and a high number of drug overdose deaths reported.








SCNX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Scienture Holdings Inc 13.11 0.15 -41.85 9
SUBTOTAL 0.00 0.00 0.00 -

Sources: Scienture Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Scienture Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Scienture Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.